Invesaro

Stocks Comparison

HeartSciences vs ZeroStack: revenue, profit, margins and growth compared

HeartSciences brought in $4.3K of revenue in fiscal 2026, ZeroStack $35.7M in fiscal 2025. Revenue changed by -0.7% at HeartSciences and -0.5% at ZeroStack on the year before, so ZeroStack grew faster. HeartSciences kept -211,666.5% of its revenue as net profit, ZeroStack -335.6%. Free cash flow was -$7.4M at HeartSciences and -$8.8M at ZeroStack.

Side by side, latest fiscal year

HSCSZSTK
Fiscal year endedFY2026 (April 30, 2026)FY2025 (December 31, 2025)
Revenue$4.3K$35.7M
Revenue growth-0.7%-0.5%
Net income-$9.1M-$119.7M
Net margin-211,666.5%-335.6%
Free cash flow-$7.4M-$8.8M
Free cash flow margin-172,036.6%-24.7%
Earnings per share (diluted)-$3.48-$43.49
Cash$1.7M$5.6M
Debtn/a$53.5M
Price to earningsn/an/a
Market value$18.4M$71.2M
Dividend yieldn/an/a
Rank by revenue in sector#646 of 646 · Health care#402 of 646 · Health care

Over the years

Revenue
HSCS FY2023: $14.4KHSCS FY2023: $5.2KHSCS FY2024: $18.6KHSCS FY2025: $4.4KHSCS FY2026: $4.3KZSTK FY2021: $106KZSTK FY2021: $9MZSTK FY2022: $33.4MZSTK FY2023: $76.1MZSTK FY2024: $35.9MZSTK FY2025: $35.7MFY21FY22FY23FY24FY25FY26
HSCS $4.3KZSTK $35.7M
Net income
HSCS FY2023: -$4.8MHSCS FY2023: -$6.4MHSCS FY2024: -$6.6MHSCS FY2025: -$8.8MHSCS FY2026: -$9.1MZSTK FY2021: -$14.3MZSTK FY2021: -$21.4MZSTK FY2022: -$52.4MZSTK FY2023: -$57MZSTK FY2024: -$15.9MZSTK FY2025: -$119.7MFY21FY22FY23FY24FY25FY26
HSCS -$9.1MZSTK -$119.7M
Net margin
HSCS FY2023: -33,592.6%HSCS FY2023: -123,384.3%HSCS FY2024: -35,511.9%HSCS FY2025: -201,499.5%HSCS FY2026: -211,666.5%ZSTK FY2021: -13,522.6%ZSTK FY2021: -237.9%ZSTK FY2022: -156.9%ZSTK FY2023: -75.0%ZSTK FY2024: -44.4%ZSTK FY2025: -335.6%FY21FY22FY23FY24FY25FY26
HSCS -211,666.5%ZSTK -335.6%
Revenue growth
HSCS FY2023: -64.2%HSCS FY2024: +261.2%HSCS FY2025: -76.6%HSCS FY2026: -0.7%ZSTK FY2021: +8,371.7%ZSTK FY2022: +271.9%ZSTK FY2023: +127.8%ZSTK FY2024: -52.9%ZSTK FY2025: -0.5%FY21FY22FY23FY24FY25FY26
HSCS -0.7%ZSTK -0.5%
Free cash flow
HSCS FY2023: -$3.6MHSCS FY2023: -$5.8MHSCS FY2024: -$6.1MHSCS FY2025: -$7.4MHSCS FY2026: -$7.4MZSTK FY2021: -$8.4MZSTK FY2021: -$24.9MZSTK FY2022: -$17.2MZSTK FY2023: -$8.6MZSTK FY2024: -$5.2MZSTK FY2025: -$8.8MFY21FY22FY23FY24FY25FY26
HSCS -$7.4MZSTK -$8.8M

Fiscal years as each company reports them; the two may end in different months.

Questions about HeartSciences and ZeroStack

Which is bigger by revenue, HeartSciences or ZeroStack?

ZeroStack is bigger by revenue: $35.7M in fiscal 2025, against $4.3K for HeartSciences in fiscal 2026.

Which keeps more of its revenue as profit, HeartSciences or ZeroStack?

HeartSciences had a net margin of -211,666.5% in fiscal 2026; ZeroStack had -335.6% in fiscal 2025.

Which grew revenue faster, HeartSciences or ZeroStack?

In their latest fiscal years revenue changed by -0.7% at HeartSciences and -0.5% at ZeroStack.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies